Wie hoch ist der Preis für Impact Therap-b (7630)

Preis für Impact Therap-b (7630) ist $1.85

Wie hoch ist die Marktkapitalisierung für Impact Therap-b (7630)

Marktkapitalisierung für Impact Therap-b (7630) ist $510.85M

Impact Therap-b (7630) KUV

IMPACT Therapeutics, a biotechnology firm, specializes in the discovery and advancement of precision anti-cancer treatments rooted in synthetic lethality, operating across China and international markets. The company's primary offering, Senaparib (IMP4297), is a PARP1/2 inhibitor currently deployed as a first-line maintenance therapy for ovarian cancer. Beyond this, Impact Therapeutics maintains a robust pipeline of investigational drugs. This includes IMP1734, a next-generation PARP1 selective inhibitor undergoing Phase I/II trials as a standalone treatment for advanced solid tumors. Another promising candidate is IMP9064, an ATR kinase selective inhibitor, also in Phase I/II clinical studies for advanced solid tumors as a monotherapy. IMP1707, a PARP1 selective inhibitor capable of penetrating the central nervous system, is in Phase I development for homologous recombination repair-deficient tumors. Additionally, IMP7068, an advanced WEE1 inhibitor, is progressing through Phase I/II clinical trials for various advanced solid tumors. Furthermore, a range of other compounds, namely IMP22, IMP25, IMP08, IMP13, IMP10, IMP27, and IMP32, are in the preclinical development phase. The company, established in 2009, is headquartered in Shanghai, China.

Jahr	P/S-Verhältnis	ändert
Nicht genügend Daten für die angegebenen Daten.

Jahr

P/S-Verhältnis

ändert

Nicht genügend Daten für die angegebenen Daten.

Unternehmen	P/S-Verhältnis	P/S-Verhältnis-Differenz	Land
Eli Lilly and Company LLY.US	13.95	-	US
Johnson & Johnson JNJ.US	6.41	-	US
AbbVie Inc. ABBV.US	6.85	-	US
Roche Holding AG RO.SW	4.66	-	CH
Merck & Co., Inc. MRK.US	5.05	-	US

Unternehmen

P/S-Verhältnis

P/S-Verhältnis-Differenz

Land